当前位置： SCI文献检索 > NEUROLOGY期刊下所有文献 > TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.

TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.

Abstract：

OBJECTIVES:To determine whether TMEM106B single nucleotide polymorphisms (SNPs) are associated with frontotemporal lobar degeneration (FTLD) in patients with and without mutations in progranulin (GRN) and to determine whether TMEM106B modulates GRN expression. METHODS:We performed a case-control study of 3 SNPs in TMEM106B in 482 patients with clinical and 80 patients with pathologic FTLD-TAR DNA-binding protein 43 without GRN mutations, 78 patients with FTLD with GRN mutations, and 822 controls. Association analysis of TMEM106B with GRN plasma levels was performed in 1,013 controls and TMEM106B and GRN mRNA expression levels were correlated in peripheral blood samples from 33 patients with FTLD and 150 controls. RESULTS:In our complete FTLD patient cohort, nominal significance was identified for 2 TMEM106B SNPs (top SNP rs1990622, p(allelic) = 0.036). However, the most significant association with risk of FTLD was observed in the subgroup of GRN mutation carriers compared to controls (corrected p(allelic) = 0.0009), where there was a highly significant decrease in the frequency of homozygote carriers of the minor alleles of all TMEM106B SNPs (top SNP rs1990622, CC genotype frequency 2.6% vs 19.1%, corrected p(recessive) = 0.009). We further identified a significant association of TMEM106B SNPs with plasma GRN levels in controls (top SNP rs1990622, corrected p = 0.002) and in peripheral blood samples a highly significant correlation was observed between TMEM106B and GRN mRNA expression in patients with FTLD (r = -0.63, p = 7.7 × 10(-5)) and controls (r = -0.49, p = 2.2 × 10(-10)). CONCLUSIONS:In our study, TMEM106B SNPs significantly reduced the disease penetrance in patients with GRN mutations, potentially by modulating GRN levels. These findings hold promise for the development of future protective therapies for FTLD.

journal_name

Neurology

journal_title

Neurology

authors

Finch N,Carrasquillo MM,Baker M,Rutherford NJ,Coppola G,Dejesus-Hernandez M,Crook R,Hunter T,Ghidoni R,Benussi L,Crook J,Finger E,Hantanpaa KJ,Karydas AM,Sengdy P,Gonzalez J,Seeley WW,Johnson N,Beach TG,Mesulam M,

doi

10.1212/WNL.0b013e31820a0e3b

subject

Has Abstract

pub_date

2011-02-01 00:00:00

pages

467-74

issue

eissn

0028-3878

issn

1526-632X

pii

WNL.0b013e31820a0e3b

journal_volume

pub_type

杂志文章

在线工具

TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers.